TOKYO (Reuters) – Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer’s disease treatment drug.
The drug, recently granted accelerated approval in Japan, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease.
(Reporting by Mariko Katsumura; Editing by Tom Hogue)
